Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Single-cell immune profiling reveals enhanced immune fitness of endogenous and engineered T cells in patients with high-risk smoldering myeloma compared to Relapsed/Refractory myeloma following bispecific antibodies or CAR-T cell therapies.

Blood (2025) 146 (Supplement 1): 921.

https://doi.org/10.1182/blood-2025-921

Published: 2025

Journal Articles

Real-world (RW) use of fixed-duration (FD) ibrutinib+venetoclax (Ibr+Ven) in patients (pts) with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Pooled analysis of REALITY-worldwide (WW) and REALITY-2 prospective cohort studies

Blood (2025) 146 (Supplement 1): 3903.

https://doi.org/10.1182/blood-2025-3903

Published: 2025

Journal Articles

Dose and BTK occupancy relationship in the prospective Phase 2 TAILOR study: Exploratory end point analysis of the ibrutinib monotherapy cohorts in patients with previously untreated chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 3301.

https://doi.org/10.1182/blood-2025-3301

Published: 2025

Journal Articles

Early Safety and Efficacy of CAR-T Cell Therapy in Precursor Myeloma: Results of the CAR-PRISM Study Using Ciltacabtagene Autoleucel in High-Risk Smoldering Myeloma

Blood (2024) 144 (Supplement 1): 1027.

https://doi.org/10.1182/blood-2024-202676

Published: 2024

Journal Articles

First-Line Use of Daratumumab, Lenalidomide, and Dexamethasone Confers Survival Benefit Compared with Second-Line Use of Daratumumab-Based Regimens in Transplant-Ineligible Patients with Multiple Myeloma: Analysis of Different Clinical Scenarios

Rafael Fonseca, Thierry Facon, Mahmoud Hashim, Sandhya Nair, Jianming He, Eric M. Ammann, Annette Lam, Mark Wildgust, Shaji Kumar

Blood (2021) 138 (Supplement 1): 118.

https://doi.org/10.1182/blood-2021-144914

Published: 2021

Journal Articles

Incidence of Major Hemorrhage Among CLL and MCL Patients Compared to the General Elderly Population: An Analysis of the US SEER-Medicare Linked Database

Dina M Gifkins, PhD MPH, Amy Matcho, BSc, Huiying Yang, PhD MD, Yimei Xu, MD, Mary Ann Gooden, MD, Mark Wildgust, PhD

Blood (2015) 126 (23): 3268.

https://doi.org/10.1182/blood.V126.23.3268.3268

Published: 2015

Journal Articles

Comparative Evaluation of Ibrutinib in Treatment of Chronic Lymphocytic Leukemia Using Simulation Modeling

Siyang Peng, Feng Pan, Sonja Sorensen, Emily Dorman, Yingxin Xu, Rachel Sallum, Maren Gaudig, Nishan Sengupta, PhD, Mark Wildgust, Steve Sun

Blood (2014) 124 (21): 1299.

https://doi.org/10.1182/blood.V124.21.1299.1299

Published: 2014

Journal Articles

Safety Results from the United States Cohort of the Ibrutinib Early Access Treatment Protocol (EAP: MCL4001) in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Peter Martin, MD, Andre Goy, MD, Radhakrishnan Ramchandren, MD, Lucille Ferrante, MD, Vijay Reddy, MD PhD, Anil Londhe, Mark Wildgust, Tracy McGowan, MD, Nancy L Bartlett, MD

Blood (2014) 124 (21): 4461.

https://doi.org/10.1182/blood.V124.21.4461.4461

Published: 2014

Journal Articles

Evaluation of Ibrutinib in Treatment of Mantle Cell Lymphoma: A Treatment Comparison Using a Simulation Model

Siyang Peng, Feng Pan, Sonja Sorensen, Emily Dorman, Yingxin Xu, Rachel Sallum, Maren Gaudig, Nishan Sengupta, PhD, Mark Wildgust, Steve Sun

Blood (2014) 124 (21): 2596.

https://doi.org/10.1182/blood.V124.21.2596.2596

Published: 2014

Journal Articles

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)

Elias Jabbour, Hagop M. Kantarjian, Giuseppe Saglio, Juan Luis Steegmann, Neil P. Shah, Concepción Boqué, Charles Chuah, Carolina Pavlovsky, Jiří Mayer, Jorge Cortes, Michele Baccarani, Dong-Wook Kim, M. Brigid Bradley-Garelik, Hesham Mohamed, Mark Wildgust, Andreas Hochhaus

Blood (2014) 123 (4): 494–500.

https://doi.org/10.1182/blood-2013-06-511592

Published: 2014

Includes: Supplemental data

Journal Articles

Early Response (Molecular and Cytogenetic) and Long-Term Outcomes in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Analysis of DASISION 3-Year Data

Giuseppe Saglio, MD, Hagop M. Kantarjian, MD, Neil Shah, MD, PhD, Elias J. Jabbour, MD, Alfonso Quintas-Cardama, MD, Juan Luis Steegmann, MD, PhD, Concepción Boqué, MD, Charles Chuah, MD, Carolina Pavlovsky, MD, Jiří Mayer, MD, Jon Ukropec, PhD, Mark Wildgust, PhD, Andreas Hochhaus, MD

Blood (2012) 120 (21): 1675.

https://doi.org/10.1182/blood.V120.21.1675.1675

Published: 2012

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Single-cell immune profiling reveals enhanced immune fitness of endogenous and engineered T cells in patients with high-risk smoldering myeloma compared to Relapsed/Refractory myeloma following bispecific antibodies or CAR-T cell therapies.

Real-world (RW) use of fixed-duration (FD) ibrutinib+venetoclax (Ibr+Ven) in patients (pts) with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Pooled analysis of REALITY-worldwide (WW) and REALITY-2 prospective cohort studies

Dose and BTK occupancy relationship in the prospective Phase 2 TAILOR study: Exploratory end point analysis of the ibrutinib monotherapy cohorts in patients with previously untreated chronic lymphocytic leukemia

Early Safety and Efficacy of CAR-T Cell Therapy in Precursor Myeloma: Results of the CAR-PRISM Study Using Ciltacabtagene Autoleucel in High-Risk Smoldering Myeloma

First-Line Use of Daratumumab, Lenalidomide, and Dexamethasone Confers Survival Benefit Compared with Second-Line Use of Daratumumab-Based Regimens in Transplant-Ineligible Patients with Multiple Myeloma: Analysis of Different Clinical Scenarios

Incidence of Major Hemorrhage Among CLL and MCL Patients Compared to the General Elderly Population: An Analysis of the US SEER-Medicare Linked Database

Comparative Evaluation of Ibrutinib in Treatment of Chronic Lymphocytic Leukemia Using Simulation Modeling

Safety Results from the United States Cohort of the Ibrutinib Early Access Treatment Protocol (EAP: MCL4001) in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Evaluation of Ibrutinib in Treatment of Mantle Cell Lymphoma: A Treatment Comparison Using a Simulation Model

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)

Early Response (Molecular and Cytogenetic) and Long-Term Outcomes in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Analysis of DASISION 3-Year Data

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only